Khan Sidra S, Hay Roderick, Saunte Ditte Marie L
The European Academy of Dermatologists and Venerologist's Mycology Taskforce, Lugano, Switzerland.
The Dermatology Department, Withington Community Hospital, Manchester University Foundation Trust, Manchester, UK.
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1185-1191. doi: 10.1111/jdv.20146. Epub 2024 Jul 13.
There has been a global rise in cases of dermatophytosis and, in particular, recalcitrant and recurrent cases on tinea of the glabrous skin. This phenomenon, particularly prevalent in India, has been linked to the concerning rise of antifungal resistance. The challenge is amplified by a dearth of comprehensive, international data to understand the global scope and characteristics of such cases.
This study aims to collate international insights, focusing on areas outside Europe (as this was previously published), to map the extent and characteristics of clinical and, where possible, laboratory confirmed tinea of the glabrous skin through an online survey administered to dermatologists globally.
An online survey was distributed from February 2022 to July 2023 and captured data on respondents' experience of recalcitrant and recurrent tinea of the glabrous skin over the preceding 3 years.
A total of 260 responses were received spreads across 36 countries, excluding Europe. In total, 91.7% reported seeing cases of recalcitrant or recurrent tinea of the glabrous skin over the preceding 3 years. Common anatomical sites affected were the trunk and groin. T. mentagrophytes and T. rubrum were the predominant species implicated, and there were low rates of laboratory confirmed dermatophyte resistance.
The high rates of reported recalcitrant and recurrent tinea of the glabrous skin underscore an urgent need for global collaborative efforts and enhanced diagnostic measures. The findings advocate for the establishment of a standardized global disease registry, regulation of over-the-counter antifungal and steroid combinations, correlation of clinical suspicion with laboratory confirmed drug resistance and exploration of alternative therapeutic strategies to mitigate the burgeoning challenge of dermatophyte resistance.
全球皮肤癣菌病病例呈上升趋势，尤其是光滑皮肤癣菌病的顽固性和复发性病例。这种现象在印度尤为普遍，与抗真菌耐药性的令人担忧的上升有关。由于缺乏全面的国际数据来了解此类病例的全球范围和特征，这一挑战更加严峻。
本研究旨在收集国际见解，重点关注欧洲以外的地区（因为此前已有相关发表），通过对全球皮肤科医生进行在线调查，描绘临床确诊以及尽可能实验室确诊的光滑皮肤癣菌病的范围和特征。
2022年2月至2023年7月进行了一项在线调查，收集了受访者在过去3年中对顽固性和复发性光滑皮肤癣菌病的经验数据。
共收到来自36个欧洲以外国家的260份回复。总体而言，91.7%的受访者报告在过去3年中见过顽固性或复发性光滑皮肤癣菌病病例。受影响的常见解剖部位是躯干和腹股沟。须癣毛癣菌和红色毛癣菌是主要涉及的菌种，实验室确诊的皮肤癣菌耐药率较低。
报告的顽固性和复发性光滑皮肤癣菌病的高发病率凸显了全球合作努力和加强诊断措施的迫切需求。研究结果主张建立标准化的全球疾病登记册，规范非处方抗真菌和类固醇组合药物，将临床怀疑与实验室确诊的耐药性相关联，并探索替代治疗策略，以应对皮肤癣菌耐药性这一日益严峻的挑战。
